Abstract

Initially, Covid-19 outbreak drew the progressive economy towards regression, but later with India being seen as a prime investment destination over China exacerbating the current scenario, there is a comeback of the failed campaign ‘Make In India’ to light, with global pharmaceuticals companies eyeing on India. Therefore there emerges a need for Make In India to be catering not just the pharmaceutical companies, but it is the right time to cater to other companies, as well,  in various sectors to look at India as a profitable destination.